On May 10, 2022, LBP and Huawei signed a cooperation agreement in Guangzhou to officially join the Ascend Partner Program, and also held a seminar on the scheme of pathological data + hashrate ecology cooperation. Both parties will develop the pathological database and hashrate ecology cooperation scheme based on Ascend AI, including building a large histological AI pathological diagnosis model based on MindSpore's leading technologies in credible AI and explainable AI, and also jointly develop independent, innovative and competitive AI pathological diagnosis solutions, so as to promote the industrialization of AI in the medical field and support the prosperous development of the AI industry.
According to the agreement, LBP will become an important participant and co-constructor of Ascend AI ecology, and will join hands with Huawei to jointly develop competitive pathology database and hashrate ecology solutions based on Ascend AI basic software and hardware platform, giving full play to LBP's advantages in the field of tumor screening and precision diagnosis and in-depth service to pathology departments. In addition, the two parties will also cooperate in all aspects in the AI medical field to jointly prosper the Ascend AI ecology and promote the development of industrial innovation.
Huang Huafeng, Director of the Investment Promotion Office III under the Investment Promotion Bureau of Guangzhou Development Zone, witnessed the signing ceremony, attended the seminar and listened carefully to the sharing of the experts. In his speech, Director Huang Huafeng said that Huawei was a world-renowned technology company and an excellent representative of Chinese enterprises, LBP was a leader and pioneer in the field of pathological diagnosis in China, and the cooperation between the two parties would surely lead to profound changes in the industry and bring greater development opportunities. He hoped that the cooperation between the two parties would be solid and robust, and make a demonstration in promoting industry integration and development, AI-enabled precision medicine, and strengthening digital security and privacy protection, and wished the cooperation a major success.
"The application of artificial intelligence in pathology, which started later than imaging, is characterized by large data volume, difficult storage and complex structure, but the advantages of AI in image recognition will definitely become the future development direction of pathology." Professor Shao Chunkui, Chairman of the Pathology Branch of Guangdong Medical Association from the front line of medical treatment, is also looking forward to this cooperation, Professor Shao said that this cooperation between Huawei, an expert in AI, and LBP, who has been focusing on the pathology industry for many years, supported by the government, was expected to make breakthroughs in promoting the pathology departments towards intelligence.
Health care and AI integration and innovation
As the signatory representative, Tian Kunyang, Vice President of Huawei Ascend computing business, said that the Ascend AI industry ecosystem was an ecosystem based on the Ascend AI basic hardware and software platform, which unites excellent partners in the field of artificial intelligence to jointly build a "co-building, sharing and win-win" artificial intelligence industry. In medical fields such as tumor screening and pathological diagnosis, Huawei and LBP complement each other's strengths, and the two parties will work closely together to help the medical diagnosis industry move towards intelligence, enable social development and industrial upgrading with AI, and bring value to social development of human being.
Tian Kunyang, Vice President of Huawei Ascend computing business
"In recent years, LBP has been working intensively on the automation, standardization, digitalization and intelligence of pathology departments and the co-construction of pathology departments in primary hospitals, and found that the lack of pathologist and pathology knowledge was an obstacle for the development of the entire pathology discipline." According to Liang Zongsheng, Director and Deputy General Manager of LBP, "digitalization is the root of solving a series of problems, and intelligence is the fundamental solution to a series of problems."
LBP focuses on the R&D, production and service of tumor screening and pathological diagnostic products, and is one of the manufacturers with the most complete product lines and the most diversified products in the field of pathological diagnosis in China. Liang Zongsheng said that LBP attached great importance to the cooperation with Huawei, and would deeply integrate its profound industry accumulation with Huawei's leading technology reserve to establish a multi-dimensional database that meets the diagnostic needs of pathology departments, promote the great-leap-forward digital and intelligent development of the pathology industry, strive to build industrial model projects, and advance the development of large-scale industries.
Liang Zongsheng, Director and Deputy General Manager of LBP
Guangzhou LBP Medicine Science & Technology Co., Ltd. (stock code: 688393) focuses on tumor screening and diagnosis, and the application departments are mainly pathology departments. The Company has develop four series of product lines: liquid-based cytology (LBP), polymerase chain reaction (PCR), immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), which cover the clinical needs at different diagnostic levels from cell morphology to protein expression and gene testing in a more complete way. The Company has developed 570 pathological diagnosis-related registered/recorded products, which can be used for the screening and diagnosis of many types of tumors, and is one of the enterprises with the most abundant technology platforms and the largest variety of products in the tumor screening and diagnosis industry in China. Some of the products have been certified by CE European Union, British Standards Institute (BSI) and Japanese Ministry of Health, Labour and Welfare. The Company has established good cooperation with many authoritative hospitals, with its products applied in many Grade III-A hospitals, competing with international brands, and has been widely recognized and trusted by customers.
